Biodelivery Sciences International Inc (NASDAQ:BDSI) Sentiment Increased, Despite

Sentiment for Biodelivery Sciences International Inc (NASDAQ:BDSI)

Biodelivery Sciences International Inc (NASDAQ:BDSI) institutional sentiment increased to 2.57 in 2019 Q1. Its up 1.54, from 1.03 in 2018Q4. The ratio is better, as 54 funds started new or increased stock positions, while 21 sold and decreased their holdings in Biodelivery Sciences International Inc. The funds in our partner’s database now own: 44.55 million shares, up from 32.35 million shares in 2018Q4. Also, the number of funds holding Biodelivery Sciences International Inc in their top 10 stock positions increased from 2 to 4 for an increase of 2. Sold All: 4 Reduced: 17 Increased: 28 New Position: 26.

BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company has market cap of $393.86 million. The firm provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, which consists of a small, erodible polymer film for application to the buccal mucosa. It currently has negative earnings. It offers ONSOLIS, a fentanyl buccal soluble film to treat breakthrough pain in opioid patients with cancer; BUNAVAIL, a buprenorphine and naloxone buccal film for the treatment of opioid dependence; and BELBUCA, a buprenorphine buccal film for the treatment of chronic pain.

The stock decreased 1.35% or $0.06 during the last trading session, reaching $4.4. About 425,469 shares traded. BioDelivery Sciences International, Inc. (NASDAQ:BDSI) has risen 131.22% since June 22, 2018 and is uptrending. It has outperformed by 126.79% the S&P500.

Analysts await BioDelivery Sciences International, Inc. (NASDAQ:BDSI) to report earnings on August, 8. They expect $-0.06 earnings per share, up 62.50 % or $0.10 from last year’s $-0.16 per share. After $-0.05 actual earnings per share reported by BioDelivery Sciences International, Inc. for the previous quarter, Wall Street now forecasts 20.00 % negative EPS growth.

Broadfin Capital Llc holds 4.79% of its portfolio in BioDelivery Sciences International, Inc. for 4.38 million shares. 1492 Capital Management Llc owns 799,361 shares or 3.59% of their US portfolio. Moreover, Foresite Capital Management Ii Llc has 1.72% invested in the company for 717,133 shares. The California-based Avoro Capital Advisors Llc has invested 1.7% in the stock. Pura Vida Investments Llc, a New York-based fund reported 700,478 shares.

Since January 1, 0001, it had 0 insider buys, and 4 insider sales for $127,775 activity.

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) Ratings Coverage

Ratings analysis reveals 100% of BioDelivery Sciences Intl’s analysts are positive. Out of 5 Wall Street analysts rating BioDelivery Sciences Intl, 5 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $6 while the high is $9. The stock’s average target of $7.40 is 68.18% above today’s ($4.4) share price. BDSI was included in 13 notes of analysts from January 31, 2019. The rating was maintained by Ladenburg on Friday, March 15 with “Buy”. The stock has “Buy” rating by Cantor Fitzgerald on Thursday, March 14. The stock has “Buy” rating by Janney Capital on Friday, March 15. H.C. Wainwright maintained the stock with “Buy” rating in Friday, March 15 report. The rating was maintained by Cantor Fitzgerald on Friday, March 1 with “Buy”. The firm earned “Buy” rating on Tuesday, March 19 by SunTrust. The stock has “Buy” rating by Cantor Fitzgerald on Friday, February 22. Cantor Fitzgerald maintained the stock with “Buy” rating in Friday, March 22 report. The rating was maintained by Cantor Fitzgerald with “Buy” on Friday, March 8. The rating was reinitiated by Janney Capital on Thursday, January 31 with “Buy”.

More notable recent BioDelivery Sciences International, Inc. (NASDAQ:BDSI) news were published by: Nasdaq.com which released: “BioDelivery Sciences International (BDSI) Gains But Lags Market: What You Should Know – Nasdaq” on March 21, 2019, also Globenewswire.com with their article: “BioDelivery Sciences Investigated by Block & Leviton LLP For Violations of Federal Securities Laws – GlobeNewswire” published on March 12, 2019, Benzinga.com published: “28 Stocks Moving In Wednesday’s Pre-Market Session – Benzinga” on May 29, 2019. More interesting news about BioDelivery Sciences International, Inc. (NASDAQ:BDSI) were released by: Globenewswire.com and their article: “Antares Pharma Announces the Appointment of Peter S. Greenleaf to Company’s Board of Directors – GlobeNewswire” published on December 13, 2018 as well as Nasdaq.com‘s news article titled: “BioDelivery Sciences International (BDSI) Reports Q1 Loss, Tops Revenue Estimates – Nasdaq” with publication date: May 06, 2019.